Novavax - Model GP - Glycoprotein Vaccine

We have developed an EBOV glycoprotein vaccine candidate (Ebola GP vaccine) expressed in insect cells, using our core recombinant baculovirus technology. In 5 separate studies, carried out in collaboration with the National Institute of Allergy and Infectious Diseases, active immunization with the Ebola GP vaccine was shown to be highly immunogenic and efficacious in preventing lethal disease in non-human primates challenged with EBOV. Our 2015 Phase 1 clinical trial demonstrated that our Ebola GP vaccine is highly immunogenic in humans, well tolerated, and, in conjunction with our proprietary Matrix-M™ adjuvant, showed marked antigen dose-sparing and induced significant increases in neutralizing antibody titers. Although not in active development, our Ebola GP vaccine is a viable development opportunity in the event of dedicated funding or a partnership arrangement.